Imarket...Forget$ 20, IFRX $$$ Could go to $50.00++...Rocket about to fly.
Recent IFRX News
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 05/12/2026 10:03:13 PM
- InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares • GlobeNewswire Inc. • 05/08/2026 12:15:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/07/2026 08:01:32 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/07/2026 12:33:54 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/06/2026 08:01:35 PM
- Biotech Surges as Big Money Backs High-Stakes Kidney Disease Push • AllPennyStocks.com • 05/06/2026 04:19:54 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/06/2026 12:33:25 PM
- InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares • GlobeNewswire Inc. • 05/06/2026 12:30:00 PM
- InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases • GlobeNewswire Inc. • 05/06/2026 12:25:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/06/2026 12:09:23 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/04/2026 08:29:41 PM
- InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes • GlobeNewswire Inc. • 05/04/2026 11:30:00 AM
- InflaRx to Report First Quarter 2026 Results on May 7, 2026 • GlobeNewswire Inc. • 05/01/2026 11:30:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/28/2026 08:16:12 PM
- InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement • GlobeNewswire Inc. • 04/28/2026 11:30:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/23/2026 08:15:07 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/09/2026 08:30:28 PM
- InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor • GlobeNewswire Inc. • 04/09/2026 11:30:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/02/2026 08:19:19 PM
- InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium • GlobeNewswire Inc. • 03/31/2026 11:30:00 AM
- InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] • Edgar (US Regulatory) • 03/20/2026 11:36:38 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/19/2026 11:45:03 AM
- InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones • GlobeNewswire Inc. • 03/19/2026 11:30:00 AM
